Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-of
Immix Biopharma Inc IMMX announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted…
Immix Biopharma (IMMX) Announces FDA Approves Orphan Drug Designation for NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
FDA Orphan Drug Designation qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testingWaiver of the Prescription Drug.
Shares of Immix Biopharma, Inc. (IMMX) are up 17% on Thursday due to the announcement that the FDA has designated NXC-201 as an Orphan Drug Designation (ODD) for the treatment of Amyloid Light Chain (AL) Amyloidosis, a life-threatening blood disorder.